The Immune Landscape in Women Cancers.

Breast cancer Dendritic cells (DC) Immunotherapy Macrophages Myeloid-derived suppressor cells (MDSC) Neoadjuvant therapy (NACT) Ovarian cancer Regulatory T cells (Tregs) T cells Tumor infiltrating lymphocytes (TILs)

Journal

Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541

Informations de publication

Date de publication:
2020
Historique:
entrez: 28 3 2020
pubmed: 28 3 2020
medline: 4 9 2020
Statut: ppublish

Résumé

In this chapter, we summarize the latest findings in the field of immuno-oncology of women cancers, particularly ovarian and breast tumors. We describe the relationship between immune parameters and clinical outcomes by evaluating the contribution of different players of the tumor microenvironment, with a particular focus on different immune cell subsets and their essential role during the development of the disease, the response to standard chemotherapy, and to emerging immunotherapeutic approaches. By reviewing the molecular and genetic features of ovarian and breast cancer subtypes, we report on the multitude of factors influencing treatment outcome, with a particular interest on the possible influence of the immune system (i.e., tumor infiltrating lymphocytes, T cells, regulatory T cells, myeloid-derived suppressor cells, dendritic cells, macrophages, B cells, tumor-associated neutrophils). Finally, we discuss emerging immune targets and novel therapeutic modalities that are likely to profoundly influence clinical outcome and prognosis of breast and ovarian cancers in the next future.

Identifiants

pubmed: 32215872
doi: 10.1007/978-3-030-38862-1_8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-249

Auteurs

Eleonora Timperi (E)

INSERM U932, Institut Curie, PSL Research University, Paris, France.

Elena Vissio (E)

Department of Medical Sciences, University of Turin, Turin, Italy.

Caterina Marchiò (C)

Department of Medical Sciences, University of Turin, Turin, Italy.
FPO-IRCCS Candiolo Cancer Institute, Candiolo, Italy.

Emanuela Romano (E)

INSERM U932, Institut Curie, PSL Research University, Paris, France. emanuela.romano@curie.fr.
Department of Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, PSL Research University, Paris, France. emanuela.romano@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH